UBC9 Antibody (50): sc-136245
- UBC9 Antibody (50) is a mouse monoclonal IgG2a, cited in 1 publications, provided at 50 µg/0.5 ml
- raised against amino acids 26-156 of UBC9 of human origin
- recommended for detection of UBC9 of mouse, rat, human and canine origin by WB, IP and IF
- See UBC9 (C-12): sc-271057 for UBC9 antibody conjugates, including AC, HRP, FITC, PE, Alexa Fluor® 488, 594, 647, 680 and 790.
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for UBC9 Antibody (50). This work is in progress.
UBC9 Antibody (50) is a mouse monoclonal IgG2a antibody that detects UBC9 in mouse, rat, human, and canine samples through applications such as western blotting (WB), immunoprecipitation (IP), and immunofluorescence (IF). UBC9 plays a crucial role in the ubiquitin-mediated proteolytic pathway, which is essential for regulating protein degradation via the 26S proteasome, mediating endocytosis, and directing protein localization within the cell. UBC9 is primarily located in the nucleus, where UBC9 is involved in the modification of target proteins through a process known as sentrinization, which is vital for various cellular functions, including the regulation of gene expression and the cell cycle. UBC9 preferentially interacts with SUMO-1, a ubiquitin-like modifier, and UBC9′s activity is critical for the proper functioning of transcription factors and mitotic regulators, such as E12, E47, RanBP2, and RanGAP1. The presence of a conserved cysteine residue in UBC9 is essential for the formation of thioester bonds with SUMO proteins, highlighting the importance of structural integrity for enzymatic activity. Anti-UBC9 antibody (50) is an invaluable tool for researchers studying the dynamics of protein modification and degradation, as well as the intricate signaling pathways that govern cellular processes.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
UBC9 Antibody (50) References:
- A role for Ubc9 in tumorigenesis. | Mo, YY., et al. 2005. Oncogene. 24: 2677-83. PMID: 15735760
- Targeting the SUMO E2 conjugating enzyme Ubc9 interaction for anti-cancer drug design. | Duan, X., et al. 2009. Anticancer Agents Med Chem. 9: 51-4. PMID: 19149481
- microRNA-214-mediated UBC9 expression in glioma. | Zhao, Z., et al. 2012. BMB Rep. 45: 641-6. PMID: 23187003
- Targeting UBC9-mediated protein hyper-SUMOylation in cystic cholangiocytes halts polycystic liver disease in experimental models. | Lee-Law, PY., et al. 2021. J Hepatol. 74: 394-406. PMID: 32950589
- Ubc9 Attenuates Myocardial Ischemic Injury Through Accelerating Autophagic Flux. | Xiao, Q., et al. 2020. Front Pharmacol. 11: 561306. PMID: 33041800
- UBC9 coordinates inflammation affecting development of bladder cancer. | Huang, X., et al. 2020. Sci Rep. 10: 20670. PMID: 33244139
- Abeta-induced presynaptic release of UBC9 through extracellular vesicles involves SNAP23. | Long, Y., et al. 2022. Neurosci Lett. 785: 136771. PMID: 35792301
- The UBC9/SUMO pathway affects E-cadherin cleavage in HPV-positive head and neck cancer. | Sabatini, ME., et al. 2022. Front Mol Biosci. 9: 940449. PMID: 36032664
- Intranasal CRMP2-Ubc9 inhibitor regulates Na V 1.7 to alleviate trigeminal neuropathic pain. | Loya-Lopez, SI., et al. 2024. Pain. 165: 573-588. PMID: 37751532
- UBC9-mediated SUMOylation of Lamin B1 enhances DNA-damage-induced nuclear DNA leakage and autophagy after spinal cord injury. | Fan, YP., et al. 2024. J Cell Physiol. 239: e31213. PMID: 38308641
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
UBC9 Antibody (50) | sc-136245 | 50 µg/0.5 ml | $322.00 |